PRAME在瘢痕性和促纤维增生性黑色素瘤中的表达相似。 - Suppr

Suppr

超能文献

PRAME expression is similar in scar and desmoplastic melanoma.

作者信息

Plotzke Jaclyn M, Zoumberos Nicholas A, Hrycaj Steven M, Harms Paul W, Bresler Scott C, Chan May P

机构信息

Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA.

Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

出版信息

J Cutan Pathol. 2022 Sep;49(9):829-832. doi: 10.1111/cup.14286. Epub 2022 Jul 11.

DOI:10.1111/cup.14286

PMID:35752877

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9541680/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3fb9/9541680/29e4b60e7baf/CUP-49-829-g001.jpg

相似文献

PRAME expression is similar in scar and desmoplastic melanoma.

J Cutan Pathol. 2022 Sep;49(9):829-832. doi: 10.1111/cup.14286. Epub 2022 Jul 11.

Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.

Am J Dermatopathol. 2021 Nov 1;43(11):794-800. doi: 10.1097/DAD.0000000000001885.

The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.

Pathol Res Pract. 2020 Sep;216(9):153105. doi: 10.1016/j.prp.2020.153105. Epub 2020 Jul 11.

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.

J Cutan Pathol. 2022 Mar;49(3):220-230. doi: 10.1111/cup.14130. Epub 2021 Sep 20.

Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis.

Biomed Res Int. 2020 Dec 10;2020:8828579. doi: 10.1155/2020/8828579. eCollection 2020.

The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.

J Cutan Pathol. 2021 Sep;48(9):1115-1123. doi: 10.1111/cup.14000. Epub 2021 Mar 15.

Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.

Cancer Lett. 2017 Sep 10;403:144-151. doi: 10.1016/j.canlet.2017.06.015. Epub 2017 Jun 17.

PRAME Expression in Melanocytic Tumors.

Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.

Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.

Am J Surg Pathol. 2020 Jul;44(7):893-900. doi: 10.1097/PAS.0000000000001492.

Expression of MCSP and PRAME in conjunctival melanoma.

Br J Ophthalmol. 2010 Oct;94(10):1322-7. doi: 10.1136/bjo.2009.167445. Epub 2010 Aug 30.

引用本文的文献

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.

J Pathol. 2025 Jul 23. doi: 10.1002/path.6450.

PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.

bioRxiv. 2024 Jul 26:2024.07.26.605293. doi: 10.1101/2024.07.26.605293.

Advances in melanoma: epidemiology, diagnosis, and prognosis.

Front Med (Lausanne). 2023 Nov 22;10:1268479. doi: 10.3389/fmed.2023.1268479. eCollection 2023.

Immunohistochemistry for PRAME in Dermatopathology.

Am J Dermatopathol. 2023 Nov 1;45(11):733-747. doi: 10.1097/DAD.0000000000002440.

Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.

Virchows Arch. 2023 Dec;483(6):847-854. doi: 10.1007/s00428-023-03648-w. Epub 2023 Sep 19.

Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.

Int J Mol Sci. 2023 Mar 28;24(7):6388. doi: 10.3390/ijms24076388.

Top 10 Differential Diagnoses for Desmoplastic Melanoma.

Head Neck Pathol. 2023 Mar;17(1):143-153. doi: 10.1007/s12105-023-01536-y. Epub 2023 Mar 16.

本文引用的文献

PRAME immunoexpression in benign fibroblasts - a diagnostic pitfall.

Histopathology. 2022 May;80(6):1011-1013. doi: 10.1111/his.14615. Epub 2022 Mar 3.

PRAME expression in melanocytic lesions of the conjunctiva.

Histopathology. 2021 Dec;79(6):989-996. doi: 10.1111/his.14452. Epub 2021 Sep 5.

Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.

Am J Dermatopathol. 2021 Nov 1;43(11):794-800. doi: 10.1097/DAD.0000000000001885.

Aberrant expression of HMB45 and negative PRAME expression in halo nevi.

J Cutan Pathol. 2021 Apr;48(4):519-525. doi: 10.1111/cup.13916. Epub 2020 Nov 25.

Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.

Am J Surg Pathol. 2020 Apr;44(4):503-508. doi: 10.1097/PAS.0000000000001393.

PRAME Expression in Melanocytic Tumors.

Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.

SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens.

Pathology. 2016 Oct;48(6):626-8. doi: 10.1016/j.pathol.2016.06.009. Epub 2016 Aug 28.

Cancer/Testis antigen expression on mesenchymal stem cells isolated from different tissues.

Anticancer Res. 2010 Dec;30(12):5023-7.

SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar.

J Cutan Pathol. 2010 Sep;37(9):944-52. doi: 10.1111/j.1600-0560.2010.01568.x.

Cancer/testis antigens, gametogenesis and cancer.

Nat Rev Cancer. 2005 Aug;5(8):615-25. doi: 10.1038/nrc1669.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

PRAME expression is similar in scar and desmoplastic melanoma.

J Cutan Pathol. 2022 Sep;49(9):829-832. doi: 10.1111/cup.14286. Epub 2022 Jul 11.

Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.

Am J Dermatopathol. 2021 Nov 1;43(11):794-800. doi: 10.1097/DAD.0000000000001885.

The diagnostic utility of PRAME and p16 in distinguishing nodal nevi from nodal metastatic melanoma.

Pathol Res Pract. 2020 Sep;216(9):153105. doi: 10.1016/j.prp.2020.153105. Epub 2020 Jul 11.

Preferentially expressed antigen in melanoma and p16 expression in acral melanocytic neoplasms.

J Cutan Pathol. 2022 Mar;49(3):220-230. doi: 10.1111/cup.14130. Epub 2021 Sep 20.

Clinicopathological and Prognostic Significance of PRAME Overexpression in Human Cancer: A Meta-Analysis.

Biomed Res Int. 2020 Dec 10;2020:8828579. doi: 10.1155/2020/8828579. eCollection 2020.

The utility of PRAME immunohistochemistry in the evaluation of challenging melanocytic tumors.

J Cutan Pathol. 2021 Sep;48(9):1115-1123. doi: 10.1111/cup.14000. Epub 2021 Mar 15.

Tumor antigen PRAME is up-regulated by MZF1 in cooperation with DNA hypomethylation in melanoma cells.

Cancer Lett. 2017 Sep 10;403:144-151. doi: 10.1016/j.canlet.2017.06.015. Epub 2017 Jun 17.

PRAME Expression in Melanocytic Tumors.

Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.

Comparison of Immunohistochemistry for PRAME With Cytogenetic Test Results in the Evaluation of Challenging Melanocytic Tumors.

Am J Surg Pathol. 2020 Jul;44(7):893-900. doi: 10.1097/PAS.0000000000001492.

Expression of MCSP and PRAME in conjunctival melanoma.

Br J Ophthalmol. 2010 Oct;94(10):1322-7. doi: 10.1136/bjo.2009.167445. Epub 2010 Aug 30.

引用本文的文献

Enhanced diagnostic potential of CSPG4 in melanoma and nevi: a comparative study with PRAME, CDC7 and Ki67.

J Pathol. 2025 Jul 23. doi: 10.1002/path.6450.

PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation.

bioRxiv. 2024 Jul 26:2024.07.26.605293. doi: 10.1101/2024.07.26.605293.

Advances in melanoma: epidemiology, diagnosis, and prognosis.

Front Med (Lausanne). 2023 Nov 22;10:1268479. doi: 10.3389/fmed.2023.1268479. eCollection 2023.

Immunohistochemistry for PRAME in Dermatopathology.

Am J Dermatopathol. 2023 Nov 1;45(11):733-747. doi: 10.1097/DAD.0000000000002440.

Refining the application of PRAME-a useful marker in high CSD and acral melanoma subtypes.

Virchows Arch. 2023 Dec;483(6):847-854. doi: 10.1007/s00428-023-03648-w. Epub 2023 Sep 19.

Standardized Computer-Assisted Analysis of PRAME Immunoreactivity in Dysplastic Nevi and Superficial Spreading Melanomas.

Int J Mol Sci. 2023 Mar 28;24(7):6388. doi: 10.3390/ijms24076388.

Top 10 Differential Diagnoses for Desmoplastic Melanoma.

Head Neck Pathol. 2023 Mar;17(1):143-153. doi: 10.1007/s12105-023-01536-y. Epub 2023 Mar 16.

本文引用的文献

PRAME immunoexpression in benign fibroblasts - a diagnostic pitfall.

Histopathology. 2022 May;80(6):1011-1013. doi: 10.1111/his.14615. Epub 2022 Mar 3.

PRAME expression in melanocytic lesions of the conjunctiva.

Histopathology. 2021 Dec;79(6):989-996. doi: 10.1111/his.14452. Epub 2021 Sep 5.

Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.

Am J Dermatopathol. 2021 Nov 1;43(11):794-800. doi: 10.1097/DAD.0000000000001885.

Aberrant expression of HMB45 and negative PRAME expression in halo nevi.

J Cutan Pathol. 2021 Apr;48(4):519-525. doi: 10.1111/cup.13916. Epub 2020 Nov 25.

Immunohistochemistry for PRAME in the Distinction of Nodal Nevi From Metastatic Melanoma.

Am J Surg Pathol. 2020 Apr;44(4):503-508. doi: 10.1097/PAS.0000000000001393.

PRAME Expression in Melanocytic Tumors.

Am J Surg Pathol. 2018 Nov;42(11):1456-1465. doi: 10.1097/PAS.0000000000001134.

SOX10 expression in cutaneous scars: a potential diagnostic pitfall in the evaluation of melanoma re-excision specimens.

Pathology. 2016 Oct;48(6):626-8. doi: 10.1016/j.pathol.2016.06.009. Epub 2016 Aug 28.

Cancer/Testis antigen expression on mesenchymal stem cells isolated from different tissues.

Anticancer Res. 2010 Dec;30(12):5023-7.

SOX10 immunostaining distinguishes desmoplastic melanoma from excision scar.

J Cutan Pathol. 2010 Sep;37(9):944-52. doi: 10.1111/j.1600-0560.2010.01568.x.

Cancer/testis antigens, gametogenesis and cancer.

Nat Rev Cancer. 2005 Aug;5(8):615-25. doi: 10.1038/nrc1669.